Protective effects of KW-3635, a novel thromboxane A2 antagonist, in murine traumatic shock
- 1 June 1990
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 182 (1) , 1-8
- https://doi.org/10.1016/0014-2999(90)90487-q
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Efficacy of a combination thromboxane receptor antagonist and lipoxygenase inhibitor in traumatic shockResuscitation, 1988
- Characterization of a new compound, S-145, as a specific TXA2 receptor antagonist in plateletsThrombosis Research, 1988
- Thromboxane induced red blood cell lysisProstaglandins, 1987
- The biochemical pharmacology of thromboxane synthase inhibition in man.Circulation, 1985
- Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2Biochemical Pharmacology, 1984
- Correlation of Spontaneous Microaggregate Formation with the Severity of Trauma in ManPublished by Wolters Kluwer Health ,1983
- Evidence that prostaglandin endoperoxides can induce platelet aggregation in the absence of thromboxane A2 productionBiochemical Pharmacology, 1982
- Protective effects of a novel thromboxane analog in lethal traumatic shockProstaglandins and Medicine, 1979
- Pancreatic hydrolases and the formation of a myocardial depressant factor in shockAmerican Journal of Physiology-Legacy Content, 1972
- A QUANTITATIVE METHOD FOR THE PRODUCTION OF EXPERIMENTAL TRAUMATIC SHOCK WITHOUT HÆMORRHAGE IN UNANÆSTHETIZED ANIMALSQuarterly Journal of Experimental Physiology and Cognate Medical Sciences, 1942